Introduction
FLT3 (fms-like tyrosine kinase 3) is a type III receptor tyrosine kinase (RTK) closely related to the PDGF receptor and c-Kit with important functions in the regulation of early hematopoietic cells. FLT3 is frequently mutated in patients with acute myeloid leukemia (AML) which correlates with poor prognosis and decreased patient survival. [1] [2] [3] [4] The most common mutations are internal tandem duplications (ITD) of the juxtamembrane domain, which cause ligand-independent dimerization and autophosphorylation. FLT3-ITD expression causes malignant transformation and factor-independent growth when expressed in factordependent cell lines. 5, 6 Development of RTK inhibitors selective for FLT3 has emerged as attractive drugs for treatment of AML patients. Several inhibitors have been described, such as AG1295, CEP701, PKC412, and SU-11248, with cytotoxic effects to cell lines and primary AML cells in vitro expressing mutant FLT3. PKC412 is one of several FLT3 inhibitors that is currently evaluated in late-stage clinical trials in AML patients carrying FLT3 mutations. 7 However, as single agents these inhibitors are able to sustain only limited cytotoxic responses in AML patients and relapse occurs after the initial response. [8] [9] [10] [11] Therefore combination therapy has emerged as a therapeutic strategy. Clarifying the downstream signaling components of FLT3-ITD could identify attractive targets for such intervention and enhance the long-term therapeutic benefits.
FLT3-ITD activates intracellular effector proteins mediating proliferation and
survival. The Ras pathway and constitutive phosphorylation of mitogen activated protein (MAP) kinase has been demonstrated in cells expressing FLT3-ITD. 5, 6 In primary AML blasts and in cell lines expressing FLT3-ITD, increased activation of the survival AKT kinase has been observed. [12] [13] [14] AKT is transiently activated by normal FLT3 signaling which leads to inhibition of apoptosis by phosphorylating FOXO3a, a Forkhead family member involved in apoptosis and cell cycle control. 15 Studies have confirmed that AKT inhibits FOXO3a in FLT3-ITD expressing cells, 13, 14 suggesting that the pathway could be efficient for FLT3
intervention. Phosphorylated AKT is also found in AML samples expressing wildtype FLT3, 16 indicating that overexpression of FLT3 is sufficient to trigger AKT activation.
Increasing evidence suggest that the mechanisms by which chemotherapeutic drugs and novel inhibitors eliminate malignant cells is mainly by apoptotic induction. The BH3-only proteins Bim (Bcl-2 interacting modulator of cell death) and Puma (p53 upFor personal use only. on November 16, 2017 . by guest www.bloodjournal.org From regulated modulator of apoptosis), proapoptotic members of the Bcl-2 family, can be activated in response to cytotoxic stimuli, including chemotherapeutic drugs. 17 They have a prominent role among the BH3-only proteins since they bind with high affinity to all antiapoptotic Bcl-2 family proteins, 18 thereby promoting mitochondrial release of cytochrome c, which subsequently activates caspase 9 and caspase 3 and death effector molecules. Recent results suggest that Bim and Puma have overlapping effects as well as distinct roles in vivo.
This was demonstrated in genetically modified mice in which glucocorticoid-induced apoptosis varied with cell type and was dependent on lack of Bim or Puma. 19 Hence, exploring the regulation of Bim and Puma upon chemotherapeutic treatment may prompt new developments in treatment of AML. Studies indicate that BCR-ABL protein in chronic myelogenous leukemia (CML) and oncogenic FLT3-ITD support cell survival through downregulation of Bim expression by a FOXO3a-dependent mechanism. 13, 14, [20] [21] [22] 
Establishment of cells expressing FLT3-ITD
For establishment of FDC-P1/FLT3-ITD, Phoenix-Eco cells were transfected with retroviral vector containing FLT3-ITD using standard CaPO 4 -precipitation, after which supernatants were filtered and used to infect FDC-P1 cells with 4 μ g protamine sulphate/mL (Sigma) and IL-3. Transduced cells were isolated by selection with 800 μ g G418/mL (PAA) for one week.
Selected cells were maintained in the absence of cytokine for no longer than 2 months. 
Immunoprecipitations and Western blot analysis

Patient samples
The study was approved by the research ethical committee at the Faculty of Health Sciences, Linköping, Sweden. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Bone marrow or peripheral blood samples from patients with de novo AML were subjected to Ficoll-Hypaque (GE Healthcare) density gradient centrifugation.
Multiplex PCR including digestion of amplicon with EcoRV for detection of FLT3-ITD was performed as described. 2 After capillary electrophoresis separation, PCR fragments were analysed and their lengths and peak heights estimated. Mutation amount as per cent of total DNA content was calculated from peak heights. All samples were morphologically confirmed to contain >90% leukemic blasts by May-Grünwald-Giemsa-staining on cytospins, and cells were cryopreserved in liquid nitrogen. After unthawing the samples, cells were allowed to rest for 4 hours in RPMI 1640 with 10% FBS before adding inhibitors. Effects of inhibitor on viability were studied after 72 hours by flow cytometry of propidium iodide stained cells.
Realtime PCR
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Total RNA was isolated using RNeasey mini kit (Qiagen, Hilden, Germany) and reversed transcribed to cDNA by SuperScript III Reverse Transcriptase (Invitrogen). Quantitative PCR was performed in 10 µL with 2x SYBR green mastermix (Applied Biosystems, Warrington, UK) containing DNA polymerase, dNTPs, buffer, 1 µM of forward and reverse primers, and 4-12 ng template using 7500 FAST Real-Time System (Applied Biosystems).. All samples were performed in triplicates and human β -glucuronidase (GusB) was used as an endogenous control. Primer sequences designed with Primer express software (Applied Biosystems) were as follows: GusB forward primer (5'-TGGTTGGAGAGCTCATTTGGA-3') and reverse primer (5'-ACTCTCGTCGGTGACTGTTCAG-3'); Bim forward primer (5'-TGGCAAAGCAACCTTCTGATG-3') and reverse primer (5'-GCAGGCTGCAATTGTCTACCT-3'); Puma forward primer (5'-GAAGAGCAAATGAGCCAAACG-3') and reverse primer (5'-GGAGCAACCGGCAAACG-3'). Relative expression was calculated using the 2 -∆∆Ct method.
Chromatin immunoprecipitation (ChIP) assays
ChIP was performed using a ChIP-Assay kit as recommended by the manufacturer (Upstate).
Approximately 2x10 PCR reactions with the same primers at 55ºC for 32 cycles were also performed to visualize products on 1.5% agarose gels. 
Statistical analysis
Results
The PI-3 kinase/AKT pathway elicits critical growth stimulatory and prosurvival signals in
FLT3-ITD-transduced FDC-P1 cells
We retrovirally infected the myeloid progenitor cell line FDC-P1 with a FLT3-ITD derived from an AML patient with a seven amino acid duplication (EYEYDLK) 29 spanning tyrosine residues 597 and 599 implied in the transduction of growth-promoting signals. Previously described cells expressing wildtype, non-mutated FLT3 receptor were used as controls. 
Apoptotic induction by FOXO3a in FLT3-ITD expressing cells involves Bim and Puma
To address the importance of FOXO3a inactivation by FLT3-ITD signaling, we retrovirally (expressing exclusively a mutated FLT3-ITD allele) 35 and MonoMac-6 (carrying an activated FLT3-V592A mutation) 25 cell lines were sensitive to treatment and showed a strong increase in numbers of apoptotic cells ( Figure 4A ). This was accompanied by upregulation of Bim protein ( Figure 4B ). In contrast, leukemic cell lines expressing no FLT3 (THP-1) or wildtype FLT3 (NB4, RS4) showed no sensitivity, although NB4 showed a two-fold increase of apoptotic cells after treatment with PKC412, despite no effect on Bim expression. Due to the lack of good quality antibodies, differences in the levels of Puma protein were difficult to determine. However, RNA levels of Puma and Bim were upregulated after 24 hours of treatment with AG1295 or PKC412 ( Figure 4C ). These results mark a trend by RTK inhibitors to trigger a cytotoxic response mediated by Bim, and possibly Puma, in leukemic cells expressing mutated FLT3.
Bim and Puma are upregulated in primary AML cells treated with PKC412
To assess the ability of RTK inhibitors to induce Bim or Puma, we exposed mononuclear cells Figure 6A ). We then analyzed the number of apoptotic cells after 24 hours treatment with AG1295. In contrast to control siRNA, Bim siRNA was able to increase the number of viable cells significantly ( Figure 6B ).
To confirm the role of FOXO3a upstream of Bim in FLT3-ITD inhibition, we transfected FDC-P1/FLT3-ITD cells with siRNAs to FOXO3a. As seen in Figure 6C , the expression of FOXO3a was significantly reduced after 24 hours of treatment. This was accompanied by reduction of Bim protein expression, indicating that silencing of FOXO3a affected Bim ( Figure 6D ). Next, we added RTK inhibitors at different time points after transfection (4, 24, and 48 hours, respectively), and the number of apoptotic cells was 
Bim is rate-limiting for RTK inhibitor-induced apopotosis of FLT3-ITD-expressing cells but Puma can contribute
In addition to Bim, Puma can bind to all pro-survival Bcl-2 family members and may be involved in RTK inhibitor-mediated apoptotic induction of FLT3-ITD-bearing cells. To assess this possibility, we repeated the gene silencing experiments including siRNA to Puma.
As seen in Figure 7A Figure 7D , the majority of bim -/-and bim -/-puma -/-bone marrow cells that were able to form CFU-C in the absence of cytokines formed also colonies in the presence of PKC412 (80.4±7.7% and 79.1±10.3%, respectively). In contrast, RTKinhibition reduced the colony-formation potential of both wildtype and puma -/-mice to a similar extent (32.7±8.5% and 46.6±17.3%; p<0.03 compared to Bim, respectively), confirming our results obtained in the short-term survival assays.
FOXO3a binds directly to the Bim promoter in FLT3-ITD cells treated with AG1295
Our studies indicate that FOXO3a-mediated upregulation of Bim is essential for apoptotic For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
Discussion
The mechanism of action of many anticancer drugs involves induction of apoptosis. While several genes are candidates to design strategies aiming at enhancing apoptosis, the BH3-only proteins are of special interest in that they mediate cytotoxic responses elicited by chemotherapeutic agents. 36 Studies from gene knockout mice indicate that Bim and Puma have prominent roles in the response to diverse cytotoxic stimuli, probably because they bind with comparable affinity to all prosurvival Bcl-2 family proteins. 37 Moreover, defective apoptosis promotes tumorigenesis by overexpression of prosurvival Bcl-2 family members, but also by loss or inactivation of proapoptotic relatives. Emerging evidence supports that elevated levels in particularly of Bim is a critical determinant in chemotherapy sensitivity, 38 hence Bim may also confer resistance to cytotoxic drugs in malignant cells.
Deregulated activation of FLT3 is recognized as the most common genetic alteration in AML ranging from 23%-35% in adult cases and 5%-16% in pediatric studies. 39 Multiple studies indicate that FLT3-ITD mutations confer a poor prognosis in AML patients. Recent studies have demonstrated that BCR-ABL signaling leads to FOXO3a and Bim inactivation, 20 which imatinib efficiently blocks. 22 Imatinib activates several proapoptotic BH3-only proteins, but while combined loss of Bim and Bad abrogated apoptosis, loss of Bmf or Puma had no effect, 38 indicating that different inhibitors can neutralize different BH3-only proteins.
We demonstrate that treatment with the well-documented RTK inhibitors For 
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